176 related articles for article (PubMed ID: 26116107)
1. Detecting functional changes with [(18)F]FAZA in a renal cell carcinoma mouse model following sunitinib therapy.
Chapman DW; Jans HS; Ma I; Mercer JR; Wiebe LI; Wuest M; Moore RB
EJNMMI Res; 2014 Dec; 4(1):27. PubMed ID: 26116107
[TBL] [Abstract][Full Text] [Related]
2. Comparison of three
Dos Santos SN; Wuest M; Jans HS; Woodfield J; Nario AP; Krys D; Dufour J; Glubrecht D; Bergman C; Bernardes ES; Wuest F
Nucl Med Biol; 2023; 124-125():108383. PubMed ID: 37651917
[TBL] [Abstract][Full Text] [Related]
3. Positron Emission Tomography (PET) and Pharmacokinetics: Classical Blood Sampling Versus Image-Derived Analysis of [18F]FAZA and [18F]FDG in a Murine Tumor Bearing Model.
Jans HS; Yang XH; Brocks DR; Kumar P; Wuest M; Wiebe LI
J Pharm Pharm Sci; 2018; 21(1s):32s-47s. PubMed ID: 29702045
[TBL] [Abstract][Full Text] [Related]
4. Assessment of hypoxic subvolumes in laryngeal cancer with (18)F-fluoroazomycinarabinoside ((18)F-FAZA)-PET/CT scanning and immunohistochemistry.
Bruine de Bruin L; Bollineni VR; Wachters JE; Schuuring E; van Hemel BM; van der Wal JE; Slagter-Menkema L; de Bock GH; Steenbakkers RJ; Langendijk JA; Pruim J; van der Laan BF; Halmos GB
Radiother Oncol; 2015 Oct; 117(1):106-12. PubMed ID: 26250803
[TBL] [Abstract][Full Text] [Related]
5. Y-box binding protein-1 is crucial in acquired drug resistance development in metastatic clear-cell renal cell carcinoma.
D'Costa NM; Lowerison MR; Raven PA; Tan Z; Roberts ME; Shrestha R; Urban MW; Monjaras-Avila CU; Oo HZ; Hurtado-Coll A; Chavez-Munoz C; So AI
J Exp Clin Cancer Res; 2020 Feb; 39(1):33. PubMed ID: 32041631
[TBL] [Abstract][Full Text] [Related]
6. Optimization of Early Response Monitoring and Prediction of Cancer Antiangiogenesis Therapy via Noninvasive PET Molecular Imaging Strategies of Multifactorial Bioparameters.
Bao X; Wang MW; Luo JM; Wang SY; Zhang YP; Zhang YJ
Theranostics; 2016; 6(12):2084-2098. PubMed ID: 27698942
[No Abstract] [Full Text] [Related]
7. 18F-FAZA PET imaging response tracks the reoxygenation of tumors in mice upon treatment with the mitochondrial complex I inhibitor BAY 87-2243.
Chang E; Liu H; Unterschemmann K; Ellinghaus P; Liu S; Gekeler V; Cheng Z; Berndorff D; Gambhir SS
Clin Cancer Res; 2015 Jan; 21(2):335-46. PubMed ID: 25381339
[TBL] [Abstract][Full Text] [Related]
8. Modulation of intratumoral hypoxia by the epidermal growth factor receptor inhibitor gefitinib detected using small animal PET imaging.
Solomon B; Binns D; Roselt P; Weibe LI; McArthur GA; Cullinane C; Hicks RJ
Mol Cancer Ther; 2005 Sep; 4(9):1417-22. PubMed ID: 16170034
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous targeting of Src kinase and receptor tyrosine kinase results in synergistic inhibition of renal cell carcinoma proliferation and migration.
Bai L; Yang JC; Ok JH; Mack PC; Kung HJ; Evans CP
Int J Cancer; 2012 Jun; 130(11):2693-702. PubMed ID: 21792888
[TBL] [Abstract][Full Text] [Related]
10. Monitoring therapeutic efficacy of sunitinib using [(18)F]FDG and [(18)F]FMISO PET in an immunocompetent model of luminal B (HER2-positive)-type mammary carcinoma.
Thézé B; Bernards N; Beynel A; Bouet S; Kuhnast B; Buvat I; Tavitian B; Boisgard R
BMC Cancer; 2015 Jul; 15():534. PubMed ID: 26198000
[TBL] [Abstract][Full Text] [Related]
11. Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside.
Piert M; Machulla HJ; Picchio M; Reischl G; Ziegler S; Kumar P; Wester HJ; Beck R; McEwan AJ; Wiebe LI; Schwaiger M
J Nucl Med; 2005 Jan; 46(1):106-13. PubMed ID: 15632040
[TBL] [Abstract][Full Text] [Related]
12. [
Schweifer A; Maier F; Ehrlichmann W; Lamparter D; Kneilling M; Pichler BJ; Hammerschmidt F; Reischl G
Nucl Med Biol; 2016 Dec; 43(12):759-769. PubMed ID: 27693670
[TBL] [Abstract][Full Text] [Related]
13. PET hypoxia imaging with FAZA: reproducibility at baseline and during fractionated radiotherapy in tumour-bearing mice.
Busk M; Mortensen LS; Nordsmark M; Overgaard J; Jakobsen S; Hansen KV; Theil J; Kallehauge JF; D'Andrea FP; Steiniche T; Horsman MR
Eur J Nucl Med Mol Imaging; 2013 Jan; 40(2):186-97. PubMed ID: 23076620
[TBL] [Abstract][Full Text] [Related]
14. Concomitant [
Kepes Z; Hegedus E; Sass T; Csikos C; Szabo JP; Szugyiczki V; Hajdu I; Kertesz I; Opposits G; Imrek J; Balkay L; Kalman FK; Trencsenyi G
In Vivo; 2024; 38(2):574-586. PubMed ID: 38418132
[TBL] [Abstract][Full Text] [Related]
15. Multiparametric Analysis of the Relationship Between Tumor Hypoxia and Perfusion with ¹⁸F-Fluoroazomycin Arabinoside and ¹⁵O-H₂O PET.
Iqbal R; Kramer GM; Verwer EE; Huisman MC; de Langen AJ; Bahce I; van Velden FH; Windhorst AD; Lammertsma AA; Hoekstra OS; Boellaard R
J Nucl Med; 2016 Apr; 57(4):530-5. PubMed ID: 26659349
[TBL] [Abstract][Full Text] [Related]
16. Initial results of hypoxia imaging using 1-alpha-D: -(5-deoxy-5-[18F]-fluoroarabinofuranosyl)-2-nitroimidazole ( 18F-FAZA).
Postema EJ; McEwan AJ; Riauka TA; Kumar P; Richmond DA; Abrams DN; Wiebe LI
Eur J Nucl Med Mol Imaging; 2009 Oct; 36(10):1565-73. PubMed ID: 19430784
[TBL] [Abstract][Full Text] [Related]
17. Mechanism-Specific Pharmacodynamics of a Novel Complex-I Inhibitor Quantified by Imaging Reversal of Consumptive Hypoxia with [
Gammon ST; Pisaneschi F; Bandi ML; Smith MG; Sun Y; Rao Y; Muller F; Wong F; De Groot J; Ackroyd J; Mawlawi O; Davies MA; Gopal YNV; Di Francesco ME; Marszalek JR; Dewhirst M; Piwnica-Worms D
Cells; 2019 Nov; 8(12):. PubMed ID: 31766580
[TBL] [Abstract][Full Text] [Related]
18. A prospective clinical study of ¹⁸F-FAZA PET-CT hypoxia imaging in head and neck squamous cell carcinoma before and during radiation therapy.
Servagi-Vernat S; Differding S; Hanin FX; Labar D; Bol A; Lee JA; Grégoire V
Eur J Nucl Med Mol Imaging; 2014 Aug; 41(8):1544-52. PubMed ID: 24570097
[TBL] [Abstract][Full Text] [Related]
19. Cellular Adaptation to VEGF-Targeted Antiangiogenic Therapy Induces Evasive Resistance by Overproduction of Alternative Endothelial Cell Growth Factors in Renal Cell Carcinoma.
Han KS; Raven PA; Frees S; Gust K; Fazli L; Ettinger S; Hong SJ; Kollmannsberger C; Gleave ME; So AI
Neoplasia; 2015 Nov; 17(11):805-16. PubMed ID: 26678908
[TBL] [Abstract][Full Text] [Related]
20. PET imaging of tumor hypoxia using 18F-fluoroazomycin arabinoside in stage III-IV non-small cell lung cancer patients.
Bollineni VR; Kerner GS; Pruim J; Steenbakkers RJ; Wiegman EM; Koole MJ; de Groot EH; Willemsen AT; Luurtsema G; Widder J; Groen HJ; Langendijk JA
J Nucl Med; 2013 Aug; 54(8):1175-80. PubMed ID: 23753185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]